While Veeva Systems (NYSE:VEEV) shares are dipping close to 7% after a print that failed to impress the Street, Canaccord’s Richard Davis highlights enticing long-term “value build” at play with this healthcare investment.
Veeva Systems Is Worth the Buy Longer-Term, Says Canaccord
